


Hamamatsu University's Clinical Database: D*D

☞ 73,709,298 records of 10 years of Lab. results, Prescriptions, Diagnoses,,

☞ "Pravastatin (any titer, with generics) prescribed and recorded AST > 150 within two weeks" resulted in "83 Patients", took 112.22 seconds

☞ Even in Note PC!

Michio Kimura M.D. Ph.D. Hamamatsu University School of Medicine



Search examples in Hamamatsu University Hospital

☞ In 2007, number of patients with HbA1c=6.6-8.0, then examined again in 2-3 months

- ☑ -5.8: 55 cases, 5.9-6.5: 289 cases, 6.6-8.0: 657 cases, 8.1+: 192 cases

☞ "Gemzar"(gemcitabine, a cytosine-antimetabolites) injected patient: 181 cases

- ☑ "After the injection" interstitial pneumonia (ICD-10 J84.x) diagnosed case: 7 cases

☞ Stroke onset, and within 3 years recurrence?

- ☑ Classification "Stroke" is not reliable, as it can be used for reimbursement reasons of CT scan.

Michio Kimura M.D. Ph.D. Hamamatsu University School of Medicine

Side effects noted with lab results in package insert 3 year case search before and after first medication

Itraconazole™ (Itrazole)(Cor:30ml/min) <table border="1"> <tr><td>O</td><td></td><td>X</td></tr> <tr><td>O</td><td>8</td><td>4</td></tr> <tr><td>X</td><td>7</td><td>445</td></tr> </table>	O		X	O	8	4	X	7	445	Valixa™ (Valganciclovir hcl)(PT<2) <table border="1"> <tr><td>O</td><td></td><td>X</td></tr> <tr><td>O</td><td>1</td><td>1</td></tr> <tr><td>X</td><td>1</td><td>22</td></tr> </table>	O		X	O	1	1	X	1	22	BezatoSR™ (Bezafibrate)(Cr>2m) <table border="1"> <tr><td>O</td><td></td><td>X</td></tr> <tr><td>O</td><td>2</td><td>3</td></tr> <tr><td>X</td><td>5</td><td>214</td></tr> </table>	O		X	O	2	3	X	5	214
O		X																											
O	8	4																											
X	7	445																											
O		X																											
O	1	1																											
X	1	22																											
O		X																											
O	2	3																											
X	5	214																											
Akeran™ (melphalan)(WBC<2000) <table border="1"> <tr><td>O</td><td></td><td>X</td></tr> <tr><td>O</td><td>35</td><td>7</td></tr> <tr><td>X</td><td>14</td><td>38</td></tr> </table>	O		X	O	35	7	X	14	38	activacin™ (Alteplase)(Pt<50000) <table border="1"> <tr><td>O</td><td></td><td>X</td></tr> <tr><td>O</td><td>3</td><td>0</td></tr> <tr><td>X</td><td>5</td><td>0</td></tr> </table>	O		X	O	3	0	X	5	0	Lipidi™ (Fenofibrate)(C>2.5mg/d) <table border="1"> <tr><td>O</td><td></td><td>X</td></tr> <tr><td>O</td><td>1</td><td>1</td></tr> <tr><td>X</td><td>3</td><td>77</td></tr> </table>	O		X	O	1	1	X	3	77
O		X																											
O	35	7																											
X	14	38																											
O		X																											
O	3	0																											
X	5	0																											
O		X																											
O	1	1																											
X	3	77																											
Alkeran™ (melphalan)(Pt<50000) <table border="1"> <tr><td>O</td><td></td><td>X</td></tr> <tr><td>O</td><td>27</td><td>1</td></tr> <tr><td>X</td><td>14</td><td>35</td></tr> </table>	O		X	O	27	1	X	14	35	Imuran™ (Azathioprine)(WBC<2000) <table border="1"> <tr><td>O</td><td></td><td>X</td></tr> <tr><td>O</td><td>5</td><td>10</td></tr> <tr><td>X</td><td>18</td><td>128</td></tr> </table>	O		X	O	5	10	X	18	128	Benet™ (Sodium Risedronate)(Cr<3) <table border="1"> <tr><td>O</td><td></td><td>X</td></tr> <tr><td>O</td><td>5</td><td>6</td></tr> <tr><td>X</td><td>9</td><td>438</td></tr> </table>	O		X	O	5	6	X	9	438
O		X																											
O	27	1																											
X	14	35																											
O		X																											
O	5	10																											
X	18	128																											
O		X																											
O	5	6																											
X	9	438																											
Fludara™ (Fludarabine)(Cor<30ml/min) <table border="1"> <tr><td>O</td><td></td><td>X</td></tr> <tr><td>O</td><td>2</td><td>1</td></tr> <tr><td>X</td><td>2</td><td>100</td></tr> </table>	O		X	O	2	1	X	2	100	Selara™ (Eplerenone)(Cor<50ml) <table border="1"> <tr><td>O</td><td></td><td>X</td></tr> <tr><td>O</td><td>2</td><td>2</td></tr> <tr><td>X</td><td>3</td><td>39</td></tr> </table>	O		X	O	2	2	X	3	39	Clexane™ (Enoxaparin)(Cor<30ml) <table border="1"> <tr><td>O</td><td></td><td>X</td></tr> <tr><td>O</td><td>1</td><td>1</td></tr> <tr><td>X</td><td>0</td><td>58</td></tr> </table>	O		X	O	1	1	X	0	58
O		X																											
O	2	1																											
X	2	100																											
O		X																											
O	2	2																											
X	3	39																											
O		X																											
O	1	1																											
X	0	58																											

Michio Kimura M.D. Ph.D. Hamamatsu University School of Medicine

Odds ratio against control

- All newly introduced drugs(2007-2009) medicated patients were checked of 5 lab results before/after first medication
- 4th grade medical student's research report

	Control	AST	BUN	CK	Albumin	WBC
Abilify(R) Aripiprazole	Akineton(R) BiperidenHCl	1.388	1.378	0.751	3.182	0.282
Vesamax(R) MexifloxacinHCl	Tarivid(R) Ofloxacin	1.108	0.394			1.56
Celecox(R) Celecoxib	Voltaren(R) DiclofenacNa	2.015		0.741	3.523	0.794
Orvesco(R) Ciclosoride	Salavent(R) Salmeterol				8.25	1.34
Gabapex(R) Gabapentin	Akineton(R) BiperidenHCl		0.005		1.174	5.895
Comtan(R) Entacapone	Akineton(R) BiperidenHCl			2.19		0.895
Creastol(R) RosuvastatinCa	Miyvelon(R) Pravastatin	0.501	2.217	4.052	11.57	0.872
ReQuip(R) RisperidoleHCl	Akineton(R) BiperidenHCl					12.33

Michio Kimura M.D. Ph.D. Hamamatsu University School of Medicine

Pilot study by PMDA for 5 Shizuoka hospitals (total 3500 beds), which have D*D clinical search

- For events which can be evaluated by lab results, disease classifications, DPC classifications, non-intervening search can be done
- Year 1: 2009
- 8 known adverse events

Michio Kimura M.D. Ph.D. Hamamatsu University School of Medicine

Theme 1

- Neuroleptic Malignant Syndrome by Olanzapine
- ICD10: G210
- CPK>1000

Michio Kimura M.D.

種別テーマ①: オランザピンによる悪性症候群
対象者検索条件(新規処方症例)

主条件
A) 対象期間: 2007年7月1日~2010年1月31日
B) 対象薬: オランザピン[®]の処方あり
C) 投与時年齢: 20歳以上

除外条件
D) 対象期間: 2007年4月1日~2007年6月30日
E) 対象薬: オランザピンの処方あり
投与時年齢設定なし

対象者 条件式: (A) and (B) and (C) not (D) and (E)

ケース検索条件(副作用発現症例)
a) 病名: オランザピンの全処方から2か月以内に悪性症候群(ICD10: G210)確定診断あり
主条件
b) 臨床検査値: オランザピンの全処方から2か月以内にCPK1000 IU/L以上
除外条件
c) 臨床検査値: オランザピンの初回投与3週間前にCPK1000 IU/L以上
d) 処方: オランザピンの全処方から2か月以内にダントロネトリウム(注射薬)の処方あり
ケース 条件式: [a] or (b) not c) or d) and 対象者

Post Market Adverse Event Report

- Paper-based
- Manually collected in busy clinics



Michio Kimura M.D. Ph.D. Hamamatsu University School of Medicine

Form Filling

- Manually
- But, most items are in CPOE and EMR




Michio Kimura M.D. Ph.D. Hamamatsu University School of Medicine

Medical Laboratory System Screenshot

Item	Value	Reference Range	Unit
WBC	11.5	4.0 - 10.0	10 ⁹ /L
CRP	8.6	0.0 - 3.0	mg/L
AST	1.388	0.0 - 37.0	U/L
BUN	1.378	0.0 - 20.0	mg/dL
CK	0.751	0.0 - 10.0	U/L
Albumin	3.182	3.5 - 5.0	g/dL
WBC	0.282	4.0 - 10.0	10 ⁹ /L

The screenshot shows a complex medical information system interface. On the left, there are navigation menus and patient information. The main area displays a table with columns for 'Date', 'Status', 'Medication', 'Diagnosis', 'Examination', and 'Treatment'. Below this, there is a detailed table of medical history with columns for 'Date', 'Time', 'Vital Signs', 'Lab Results', and 'Notes'. The interface is in Japanese and includes various icons and buttons for navigation and data entry.



CPOE(Computerized Physician's Order Entry) in Japan

- 90%+ in large hospitals (400+ beds)
- Top 2 vendors became able to export patient demographics, prescriptions, lab results, diagnoses, in HL7 v.2 messages
- 594 hospitals (March 2010)
- MHLW standard designation ...March 2010
- HL7 v2.5, HL7 CDA R2, DICOM and IHE PDI, Codes (ICD10 disease code, drug code, lab exam code)

Michio Kimura M.D. Ph.D. Hamamatsu University School of Medicine

MHLW notification

30 May 2010
Director Health Policy Bureau
Director Health Insurance Bureau

Notification concerning IT standards to be adopted

1. MHLW Standards
 Fullfills are to be designated as MHLW standards:
 Standard Master for Pharmacology of Products (NOT reference number)
 ED10 Based Standard Disease Code Master for Electronic Medical Records
 Patient Referral Document & Clinical Data Document
 Standard for medical equipment for hospitals
 IHE: PDI/Portable Data for Imaging Integration Profile, or Its Application Guideline
 ISO: TS 11173-10001/2007 Health informatics -- Medical workflow format -- Part 10001
 Encoding rules
 Digital Imaging and Communications in Medicine (DICOM)
 The JCR42 Protocol for Clinical Laboratory Data Communication

2. Evaluation
 When medical information systems are built or modified in a health care facility, it is very valuable from view points of information availability to implement systems according to MHLW standards. It is also useful for improving healthcare cooperation systems and medical safety. And it is essential to help communication and interoperability for medical information systems.
 So after this, the implementation of MHLW standards are required for new system and update of existing information systems by MHLW.

3. March 2010
 8 standards to be used for future reimbursements, ministry projects

HL7 v2.5, CDA, DICOM, IHE PDI, Codes(ICD10, Rx, Lab), etc.

Michio Kimura M.D. Ph.D. Hamamatsu University School of Medicine

The screenshot shows a Japanese government document or report. It contains several sections of text in Japanese, including a title and a list of items. The text is dense and appears to be a formal document.

Cabinet's office unveiled (June 2010) 5 healthcare IT roadmaps

- 「どこでもMy病院」
"My clinic, everywhere", PHR project
- 「シームレスな地域連携医療」
"Seamless regional healthcare"
- 「レセプト情報の活用による医療の効率化」
"Efficient healthcare by reimbursement data"

Michio Kimura M.D. Ph.D. Hamamatsu University School of Medicine

Cabinet's office unveiled (June 2010)
5 healthcare IT roadmaps (cont.)

- ⌘ 「医療情報データベースの活用による医薬品等安全対策」
 - ☒ "Pharmacovigilance by HIS data"
- ⌘ 「高齢者在宅医療介護見守り支援」
 - ☒ "Home care for elderly by IT"

Michio Kimura M.D. Ph.D. Hamamatsu University School of Medicine

End of presentation



Maracana Stadium, Rio de Janeiro

Michio Kimura M.D. Ph.D. Hamamatsu University School of Medicine


8. M. Kimura,, YC Li, YS Kwak :

Survey for Asia-Pacific

Countries/Regions; What are the Medical,
Records for?

MEDINFO 2010, 13th World Congress on Medical
and Health Informatics,

Cape Town, South Africa, September 13,
2010.




MEDINFO

2010

CAPE TOWN
SOUTH AFRICA

13th World Congress on Medical
and Health Informatics

12th to 15th September 2010



CAPE TOWN
International
Convention Centre



International
Medical
Informatics
Association



CONFERENCE PROGRAMME



PROGRAMME OVERVIEW - MONDAY 13 SEPTEMBER 2010

TIME:	VENUE:	ACTIVITY:
08h30 – 10h00	Audi 1	Student Paper Awards
Session 1		Plenary 2 Dr Marion Ball Prof Reinhold Haux
10h00 -10h30	Exhibition Hall 4	Break
Session 2		Parallel Session
10h30 – 12h15		Papers
	1.4.1 & 1.4.2	Public Health Informatics I
	1.4.3 & 1.4.4	Translational Bioinformatics
	1.6.1 & 1.6.2	Interoperability Issues
	1.6.3 & 1.6.4	Specialised Registries
	2.4.1 & 2.4.2	Adoption Determinants
	2.4.4 & 2.4.5	Implementation
	2.6.1 & 2.6.2	Intelligent Analysis of Monitoring Data
	2.6.4 & 2.6.5	Emerging Technologies
	Audi 1	Surveillance
	Roof Terrace	Mining Clinical Narratives
12h15 – 13h30	Exhibition Hall 4	Lunch Poster Session & Poster Tours 1
13h30 – 15h00		Parallel Session
Session 3		Papers
	1.4.1 & 1.4.2	System Usability
	1.4.3 & 1.4.4	Coding and Terminologies
	1.6.1 & 1.6.2	Citizen-Centric eHealth
		Panels
	1.6.3 & 1.6.4	979 HON code Certification: 13 years of services for improving the quality of health online information
	2.4.1 & 2.4.2	963 Accelerating the Translation of Knowledge into Clinical Decision Support: Four National Demonstration Projects
	2.4.4 & 2.4.5	875 Information Models for Supporting Semantic Interoperability and System Development: Collaborative Efforts from the Domain
	2.6.1 & 2.6.2	757 Automatic data analysis in Biomedicine: Applications and Challenges
	Roof Terrace	518 Social Media – New Tools for Personal Health and Wellbeing
	Audi 1	441 Survey for Asia-Pacific Countries/Regions; “What are the Medical Records for?”
15h00 – 15h30	Exhibition Hall 4	Break
15h30 – 17h15		Parallel Session
Session 4		Papers
	Audi 1	Nursing Informatics
	1.4.1 & 1.4.2	Telemedicine

Correct at date of print - 20 August 2010

13

MEDINFO 2010 |
CAPE TOWN INTERNATIONAL
CONVENTION CENTRE

TIME:	VENUE:	ACTIVITY:
	Audi 1	441: Survey for Asia-Pacific Countries/Regions; What are the Medical Records for? (M Kimura, YC Li, YS Kwak)
15h00 15h30	Exhibition Hall 4	Break
15h30 17h15		Parallel Session
Session 4		Papers
	Audi 1	<p>Nursing Informatics Chair: Heimar Marin</p> <p>120: Clinical users prospective on telemonitoring of patients with long term conditions: understood through concepts of Giddens s structuration theory & consequence of Modernity (U Sharma, M Clarke)</p> <p>176: Analysis on data captured by barcode medication administration system with PDA for reducing medical error at point of care in Japanese Red Cross Kochi Hospital. (M Akiyama, A Koshio, N Kaihotsu)</p> <p>993: Foundations for a Nursing Services Reference Model (L Heslop, K Toh, E Hovenga)</p> <p>653: Ambulatory orthopaedic surgery patients knowledge with Internet-based education (K Heikkinen, S Salanterä, H Leino-Kilpi)</p>
	1.4.1 & 1.4.2	<p>Telemedicine Chair: Maurice Mars</p> <p>859: Leapfrogging Paper-Based Records Using Handheld Technology: Experience from Western Kenya (M Were, J Kariuki, V Chepng'eno, M Wandabwa, S Ndege, P Braitstein, J Wachira, S Kimaiyo, B Mamlin)</p> <p>59: Cell phone Short Messaging Services (SMS) in Health care pertaining to HIV/AIDS in South Africa. (KC Mukund Bahadur, P J. Murray)</p> <p>203: Deploying Portable Ultrasonography with Remote Assistance for Isolated Physicians in Africa: Lessons from a Pilot Study in Mali (CO Bagayoko, M Niang, ST Traoré, G Bediang, JM Naef, A Geissbuhler)</p> <p>774: Exploring Feasibility of Home Telemanagement in African Americans with Congestive Heart Failure (J Finkelstein, E Cha, C Dennison)</p> <p>224: A Configurable Home Care Platform for Monitoring Patients with Reminder Messaging and Compliancy Tracking Services (D Capozzi, G Lanzola)</p>
	1.4.3 & 1.4.4	<p>Communication and Workflow Issues Chair: Nicola (Nikki) Shaw</p> <p>212: Why is it so difficult to measure the effects of interruptions in healthcare? (F Magrabi, SYW Li, AG Dunn, E Coiera)</p> <p>397: Impact of a Critical Care Clinical Information System on Interruption Rates During Intensive Care Nurse and Physician Documentation Tasks (M Ballermann, N Shaw, K Arbeau, D Mayes, N Gibney)</p> <p>749: Peri-operative Communication Patterns and Media Usage Implications for Systems Design (ES Karlsen, P Toussaint)</p> <p>806: Do CPOE Actually Disrupt Physicians-Nurses Communications? (S Pelayo, F Anceaux, J Rogalski, MC Beuscart-Zephir)</p> <p>839: The Avoidable Misfortune of a Computerised Patient Chart (I Sørby, G Seland, Ø Nytrø)</p>



**APAMI Panel:
What are the Medical Records
for?**

Michio Kimura, Jack Li, CP Wong

continued and revised from the
panel at Hiroshima, Nov 2009



APAMI2009

**Survey on Medical Records and EHR
to Asia-Pacific delegates**

Peter Croll(AU), BaoLuo Li(CN), CP
Wong(HK), SB Gogia(ID), Anis Fuad(IN),
Michio Kimura(JP), YunSik Kwak(KR),
Stephen Chu(NZ), Alvin Marcelo(PH),
ChowYuen Ho(SG), Wansa Paoin (TH),
YuChuan Li(TW)

APAMI2009

**Questionnaire sent to APAMI
delegates (12 valid answers)**

- ⌘ Purpose of medical records is primary for healthcare itself, what are 2nd? 3rd?
- ⌘ Do your country/region has national ID? national health ID?
- ⌘ What is the status of your country/region's EHR(lifelong health record) project status?
 - Purpose of EHR is primary for continuity of care, what are 2nd? 3rd?

APAMI2009 Michio Kimura M.D. Ph.D. Hamamatsu University School of Medicine

**Questionnaire sent to APAMI
delegates (12 valid answers)(cont'd)**

- ⌘ What language is used for; medical records? nursing records?
- ⌘ Disclosure of medical record contents to patient, referred physician, insurance payer, public health dept., health policy dept. are unconditional/conditional/prohibited?
- ⌘ Secondary use of medical record (dis-identified) by public health dept., health policy dept., non-profit research, for-profit research, are unconditional/conditional/prohibited? Any general regulations?

APAMI2009 Michio Kimura M.D. Ph.D. Hamamatsu University School of Medicine

Follow-up questionnaires on ID (1)

- ⌘ Does your country/region have unique ID for residents?
 - If YES, the ID is used/linkable to following purposes?
 - Healthcare claim person number
 - Healthcare record patient number at each provider
 - Healthcare record patient number among providers (unique EHR patient number)
 - Pension record number
 - Taxpayer's number
 - Driver's license number
 - Passport number
 - Employee number

APAMI2009 Hamamatsu University School of Medicine

Follow-up questionnaires on ID (2)

- ⌘ Does your country/region have unique healthcare ID for patients?
 - If YES, the ID is used/linkable to following purposes?
 - Healthcare claim person number
 - Healthcare record patient number at each provider
 - Healthcare record patient number among providers (unique EHR patient number)
 - Pension record number
 - Taxpayer's number
 - Driver's license number
 - Passport number
 - Employee number

APAMI2009 Hamamatsu University School of Medicine

Follow-up questionnaires on Privacy regulations

☞ Is there any regulation/legislation concerning secondary use of private data? (Person's ID enough anonymised, and without person's consent)

- No
- General privacy regulations only
- General privacy regulation, which puts emphasis on healthcare
- Privacy regulation, specially for healthcare

APAMI2009 Ichio Kimura M.D. Ph.D. Hamamatsu University School of Medicine

Languages used

	Medical records	Regulations on description	Nursing records	Medical school education	Nursing school education
Australia	English	Must be English	English	English	English
China	Chinese		Chinese	Chinese	Chinese
HK	English		English	English	English
India	English		English	English	English
Indonesia	Indonesia	Must be Indonesia	Indonesia	Indonesia	Indonesia
Japan	Japanese	Must be Japanese	Japanese	Japanese	Japanese
Korea	Korean & English	Must be Korean	Korean & English	Korean & English	Korean & English
NZ	English		English	English	English
Philippines	English		English	English	English
Singapore	English		English	English	English
Thailand	Thai & English		Thai & English	Thai & English	Thai & English
Taiwan	English		Chinese	Chinese	Chinese

APAMI2009 Ichio Kimura M.D. Ph.D. Hamamatsu University School of Medicine

Purpose of Medical Records, Primary is for Healthcare itself. What comes after it?

- ☞ Australia: Bill, Research, Manage, Edu, PH
- ☞ China: Manage, Bill, Research, PH, Edu
- ☞ HK: Manage, PH, Bill, Research, Edu
- ☞ India: Bill, "Protection against Litigation", Manage, PH, Edu
- ☞ Indonesia: Bill, PH, Manage, Edu, Research
- ☞ Japan: Bill, Edu, Research, Manage, PH
- ☞ Korea: Bill, Edu, Research, Manage, PH, "Legal Document"
- ☞ NZ: Manage, Bill, "Health Policy", PH, Edu, Research
- ☞ PH: Bill, Research, PH, Manage, Edu
- ☞ Singapore: Bill, PH, Manage, Research, Edu
- ☞ Thailand: Bill, Manage, Edu, Research, PH
- ☞ Taiwan: Bill, Manage, Research, Edu, PH

APAMI2009 Ichio Kimura M.D. Ph.D. Hamamatsu University School of Medicine

Does your country/region have unique ID for residents?

☞ If YES, the ID is used/linkable to following purposes?

	AU	CN	HK	IN	ID	JP	KR	NZ	PH	SG	TH	TW
YES or NO	N	Y	Y	N	Y	Y	Y	N	Y	Y	Y	Y
Healthcare Claim Number	-	N	U	-	N	N	L	-		U	U	U
Hospital/Patient Number	-	N	L	-	L	N	L	-		U	L	L
Unique EHR Number	-	N	U	-	N	N	L	-		U	N	N
Pension Record Number	-	L	U	-	N	N	L	-		U	N	U
Taxpayer's Number	-	U	L	-	N	N	L	-		U	L	U
Driver's License Number	-	L	U	-	L	N	L	-		U	L	U
Passport Number	-	N	L	-	L	L	L	-		U	L	L
Employee Number	-	L	L	-	N	N	L	-		U	N	L

APAMI2009 Ichio Kimura M.D. Ph.D. Hamamatsu University School of Medicine

unique healthcare ID for patients?

☞ If YES, the ID is used/linkable to following purposes?

	AU	CN	HK	IN	ID	JP	KR	NZ	PH	SG	TH	TW
YES, NO or Citizen ID	N	N	ID	ID	N	Y	N	Y	N	ID	ID	Y
Healthcare Claim Number	-	-	U	N	-	U	-	U		N	U	U
Hospital/Patient Number	-	-	L	L	-	L	-	N		N	L	L
Unique EHR Number	-	-	U	N	-	N	-	N		N	N	N
Pension Record Number	-	-	U	N	-	N	-	N		N	N	U
Taxpayer's Number	-	-	L	N	-	N	-	N		N	L	U
Driver's License Number	-	-	U	N	-	N	-	N		N	L	U
Passport Number	-	-	L	N	-	N	-	N		N	L	L
Employee Number	-	-	L	L	-	L	-	N		L	N	L

APAMI2009 Ichio Kimura M.D. Ph.D. Hamamatsu University School of Medicine

EHR Project Status

- ☞ Australia: Being partially tested
- ☞ China: Being partially tested
- ☞ Hong Kong: Almost accomplished
- ☞ India: No plan
- ☞ Indonesia: Being partially tested
- ☞ Japan: Being partially tested
- ☞ Korea: Being partially tested
- ☞ NZ: Being partially tested
- ☞ Philippines: No plan
- ☞ Singapore: Being partially tested
- ☞ Thailand: Being partially tested
- ☞ Taiwan: Being partially tested

APAMI2009 Ichio Kimura M.D. Ph.D. Hamamatsu University School of Medicine

Purpose of EHR, Primary is for continuation of care. What comes after it?

☞ **Prioritize among:**

- ☑ Public Health/Disease Control, Healthcare Cost Cut, Clinical Research

- ☞ Australia: 2:HCC, 3:CR, 4:PH
- ☞ China: 2:PH, 3:HCC, 4:CR
- ☞ HK: 2:HCC, 3:PH
- ☞ Indonesia: 2:HCC, 3:PH, 4:CR
- ☞ Japan: 2:HCC, 3:CR, 4:PH
- ☞ Korea: 2:HCC, 3:PH, 4:CR
- ☞ Singapore: 2:HCC, 3:PH, 4:CR
- ☞ Thailand: 2:PH, 3:CR, 4:HCC
- ☞ Taiwan: 2:HCC, 3:CR, 4:PH

Disclosure (patient name identified, without patient's consent) to;

☞ O: Unconditional, C: Conditional, X: Not done/prohibited

	The patient	Referred Dr	Insurance	Public Health	Health Policy
AU	C(Summary)	X	X	C(Infections)	C(Claim query)
CN	O	O	O	C(If Name required)	X
HK	O	O	O	X	O
ID	O	O	X	C(Notifiable Disease)	O
IN	O	O	O	O	O
JP	C(Approval)	O	C(Claim query)	C(Notifiable Disease)	X
KR	O	X	O	O	X
NZ	C(Approval)	X	C(Claim data)	C(Disease Control)	X
PH	O	O	O	C(per protocol)	C(per protocol)
SG	O	X	X	C(Infection Act)	C(Stats. Act)
TH	X	O	X	O	O
TW	X	X	X	X	X

Secondary Use (patient name enough anonymized, without consent) by ;

☞ O: Unconditional, C: Conditional, X: Not done/prohibited

	Public Health	Health Policy	non-profit	for-profit	Any reg.?
AU	O	O	O	O	O
CN	C	O	O	O	X
HK	O	O	C(Universities)	O	X
ID	O	O	C(Approval)	C(Approval)	X
IN	C(Certain Disease)	C(Certain Disease)	C(Approval)	C(Agency member)	X
JP	X	X	C(IRB)	X	O
KR	C(Outbreak)	X	X	X	O
NZ	C(No other purpose)	C(No other purpose)	C(No other purpose)	X	O
PH	O	X	X	X	X
SG	C(Stats Act)	C(Stats Act)	C(IRB)	C(IRB)	X
TH	X	X	O	X	X
TW	O	O	O	O	X

End of Presentation

☞ **Memory of APAMI 2009 in Hiroshima**

- ☑ Peace Memorial Park and Museum (next to the venue)
- ☑ Miyajima Shrine on the Sea (50 minutes boat or train ride)

